On May 21, 2026, the "2026 One BD Healthcare Investment and Financing Transaction Conference" was successfully held in Shanghai. Concurrently, the 2025 PharmaCube Annual Rankings were officially unveiled. Built on five years of accumulated insights, the rankings leverage data as their foundation and industry perspectives as their measure, outlining the core landscape of China's innovative drug industry in 2025. Biokin Pharmaceutical was successfully named to the 2025 China Innovative Drug Enterprises Global Competitive Leaders TOP 30 List.

The "2025 China Innovative Drug Enterprises Global Competitive Leaders TOP 30" List, based on PharmaCube's full-industry-chain data, comprehensively evaluates companies across multiple dimensions including overseas clinical development footprint, international BD transactions, and global commercialization capabilities, to select the benchmark enterprises at the forefront of the internationalization process of innovative drugs and with the greatest global competitive potential. The ranking aims to establish an international benchmark for the industry.